Delayed
Australian S.E.
08:50:20 2024-07-07 pm EDT
|
5-day change
|
1st Jan Change
|
0.1
AUD
|
+4.17%
|
|
+8.70%
|
-60.78%
|
Fiscal Period: Juni |
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
8.755
|
13.52
|
137.7
|
286.6
|
Enterprise Value (EV)
1 |
-3.723
|
6.415
|
126.6
|
269
|
P/E ratio
|
-1.58
x
|
-3.34
x
|
20.2
x
|
21.3
x
|
Yield
|
-
|
-
|
4%
|
1.94%
|
Capitalization / Revenue
|
70.7
x
|
7.99
x
|
2.05
x
|
2.44
x
|
EV / Revenue
|
-30.1
x
|
3.79
x
|
1.89
x
|
2.29
x
|
EV / EBITDA
|
0.91
x
|
-1.61
x
|
12.6
x
|
13.3
x
|
EV / FCF
|
1,024,760
x
|
-1,693,554
x
|
12,326,266
x
|
41,372,383
x
|
FCF Yield
|
0%
|
-0%
|
0%
|
0%
|
Price to Book
|
0.65
x
|
1.45
x
|
5.27
x
|
8.19
x
|
Nbr of stocks (in thousands)
|
128,750
|
128,750
|
550,625
|
556,532
|
Reference price
2 |
0.0680
|
0.1050
|
0.2500
|
0.5150
|
Announcement Date
|
8/28/20
|
8/27/21
|
8/28/22
|
8/22/23
|
Fiscal Period: Juni |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
0.4476
|
-
|
0.1238
|
1.693
|
66.99
|
117.3
|
EBITDA
1 |
0.2014
|
-2.864
|
-4.095
|
-3.985
|
10.09
|
20.19
|
EBIT
1 |
0.1919
|
-2.891
|
-4.125
|
-4.041
|
9.922
|
19.86
|
Operating Margin
|
42.88%
|
-
|
-3,330.34%
|
-238.7%
|
14.81%
|
16.93%
|
Earnings before Tax (EBT)
1 |
0.1923
|
-2.958
|
-3.99
|
-4.206
|
9.745
|
20.05
|
Net income
1 |
0.1503
|
-2.914
|
-3.937
|
-4.049
|
6.013
|
13.81
|
Net margin
|
33.59%
|
-
|
-3,179.02%
|
-239.2%
|
8.98%
|
11.77%
|
EPS
|
-
|
-0.9635
|
-0.0429
|
-0.0314
|
0.0124
|
0.0242
|
Free Cash Flow
|
-
|
-0.8272
|
-3.633
|
-3.788
|
10.27
|
6.503
|
FCF margin
|
-
|
-
|
-2,933.7%
|
-223.78%
|
15.34%
|
5.54%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
101.83%
|
32.21%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
170.88%
|
47.09%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
0.0100
|
0.0100
|
Announcement Date
|
11/6/19
|
11/6/19
|
8/28/20
|
8/27/21
|
8/28/22
|
8/22/23
|
Fiscal Period: June |
2023 S1
|
2023 S2
|
---|
Net sales
1 |
39.85
|
38.38
|
EBITDA
1 |
8.192
|
6.029
|
EBIT
|
-
|
-
|
Operating Margin
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
Net income
|
-
|
-
|
Net margin
|
-
|
-
|
EPS
|
-
|
-
|
Dividend per Share
|
-
|
-
|
Announcement Date
|
2/12/23
|
8/22/23
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
0.04
|
2.04
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
12.5
|
7.1
|
11
|
17.6
|
Leverage (Debt/EBITDA)
|
0.2016
x
|
-0.7132
x
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-0.83
|
-3.63
|
-3.79
|
10.3
|
6.5
|
ROE (net income / shareholders' equity)
|
-
|
214%
|
-74.5%
|
-37%
|
40%
|
45.1%
|
ROA (Net income/ Total Assets)
|
-
|
-167%
|
-28.5%
|
-17.5%
|
24%
|
27.7%
|
Assets
1 |
-
|
1.74
|
13.8
|
23.18
|
25.05
|
49.92
|
Book Value Per Share
|
-
|
-0.7000
|
0.1000
|
0.0700
|
0.0500
|
0.0600
|
Cash Flow per Share
|
-
|
0.0400
|
0.1100
|
0.0700
|
0.0300
|
0.0300
|
Capex
1 |
0.1
|
0.01
|
0.12
|
0.04
|
0.37
|
0.93
|
Capex / Sales
|
23.29%
|
-
|
97.05%
|
2.37%
|
0.55%
|
0.79%
|
Announcement Date
|
11/6/19
|
11/6/19
|
8/28/20
|
8/27/21
|
8/28/22
|
8/22/23
|
|
1st Jan change
|
Capi.
|
---|
| -60.78% | 37.29M | | +27.19% | 5.56B | | -33.59% | 3.52B | | -2.97% | 3.01B | | -24.21% | 2.65B | | -10.11% | 2.3B | | +43.66% | 1.91B | | +46.15% | 1.5B | | -13.92% | 1.41B | | +41.90% | 1.37B |
Alternative Medicine
|